| Document |
Document Title |
|
WO/2024/096569A1 |
The present invention relates to a composition, more preferably, a transdermally- or topically-administered composition, comprising, as an active ingredient, a thienopyridine compound of chemical formula 1 or a pharmaceutically acceptabl...
|
|
WO/2024/097694A1 |
The disclosure is directed to improved methods of treating minor pain in humans using a pharmaceutical dosage form comprising acetaminophen in admixture with naproxen.
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/089179A1 |
Use of dairy lipid to lower the GlycA level in a subject.
|
|
WO/2024/088311A1 |
The present invention belongs to the technical field of medicine, and specifically relates to a crystal form of an imidazopyrazine derivative represented by formula (I), a preparation method therefor and a use thereof.
|
|
WO/2024/091701A1 |
Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, f...
|
|
WO/2024/090941A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera ext...
|
|
WO/2024/088922A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
|
|
WO/2024/088109A1 |
Provided are an aryl heterocyclic compound, a preparation method therefor, and a use thereof, and the structural formula of the aryl heterocyclic compound is as shown in formula (I). The provided compound has a monoaminergic system regul...
|
|
WO/2024/092069A1 |
The present invention provides CXCR4 inhibitors of Formula (I): and pharmaceutically acceptable salts thereof, and methods for their use in treating neurological and CNS diseases, disorders, and conditions.
|
|
WO/2024/092269A1 |
The present invention relates to pharmaceutical formulations for kratom extract and mitragynine, which is the major alkaloid extracted from kratom, and use methods thereof for treatment of osteoarthritis in canine subjects.
|
|
WO/2024/091983A1 |
The present invention relates to novel compounds and compositions thereof. The compositions are useful in the treatment of an epithelial or endothelial barrier dysfunction disorder in a subject.
|
|
WO/2024/040206A9 |
The present disclosure relates to novel PD-1 agonist antibodies and methods and uses of anti-human PD-1 agonist antibodies for the treatment of autoinflammatory and/or autoimmune diseases. Also provided are doses and dosing regimens for ...
|
|
WO/2024/086919A1 |
The present disclosure provides antibodies or antigen-binding fragments thereof that bind specifically to integrin α11 (ITGA11). This disclosure also provides methods for treating a disorder in a subject, such as a fibrotic disorder, an...
|
|
WO/2024/090606A1 |
The present invention provides a method for treating posterior scleritis, comprising a first step of administering a steroid to a posterior scleritis patient through an intravenous injection, and a second step of orally administering a s...
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2024/091523A1 |
The present disclosure relates in some aspects to certain phenethylamine analogs, such as benzocyclobutene and benzocyclopentene analogs, including those of Formula (1). Also provided are methods of synthesizing the compounds, compositio...
|
|
WO/2024/088307A1 |
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
|
WO/2024/091148A2 |
The invention relates to the chemical and pharmaceutical industry, and more particularly to a liquid balneological concentrate for preparing health-giving and therapeutic full or partial baths at health resorts and in other medical and w...
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
|
WO/2024/089421A1 |
The invention relates to compounds of formula (I) and related aspects.
|
|
WO/2024/091664A1 |
This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain examples, modulators are derivatives of hexahydropental ene. In certain examples, this...
|
|
WO/2024/090571A1 |
Provided are: a method for detecting immune-mediated inflammatory diseases characterized by an increase in the expression of MMP12 in a subject; a diagnostic drug containing a substance that specifically interacts with MMP12; and a thera...
|
|
WO/2024/089046A1 |
The present invention relates to a pharmaceutical composition suitable for an intra-articular injection comprising an anesthetic agent and an immediate or controlled release dosage form comprising colchicine. It further relates to a phar...
|
|
WO/2024/090538A1 |
The present invention relates to a pharmaceutical composition for the treatment or prevention of inflammatory bowel diseases, said pharmaceutical composition containing zinc polyphosphate as an active ingredient. The zinc polyphosphate i...
|
|
WO/2024/090537A1 |
The present invention relates to a novel zinc polyphosphate, a use thereof, and a method for producing the same. More specifically, the present invention relates to: a zinc polyphosphate which is characterized by showing a halo peak at 2...
|
|
WO/2024/082917A1 |
Disclosed are a crystal form A of bupivacaine-meloxicam salt, a single crystal thereof, a preparation method therefor and a use thereof. An X-ray powder diffraction pattern of the crystal form A of the bupivacaine-meloxicam salt has char...
|
|
WO/2024/085558A1 |
The present invention relates to a composition for preventing or treating OSCAR-induced diseases, containing brivudine as an active ingredient, and a method for treating OSCAR-induced diseases, comprising the step of administering the co...
|
|
WO/2024/085557A1 |
The present invention relates to: a composition for preventing or treating OSCAR-induced diseases, comprising comprising adefovir as an active ingredient; and a method for treating OSCAR-induced diseases, comprising a step of administeri...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/085623A1 |
The present invention relates to a microbiome composition of a fermentation culture supernatant of Lactiplantibacillus plantarum strain KM2 having an anti-inflammatory effect. It has been confirmed that the fermentation culture supernata...
|
|
WO/2024/085698A1 |
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a mat...
|
|
WO/2024/085581A1 |
The present invention relates to a sustained-release injectable composition for treating or preventing an inflammatory disease, and to a method for preparing same. The present invention may continuously release cannabidiol for more than ...
|
|
WO/2024/082014A1 |
The present invention relates to compositions comprising cannabidiolic acid and fatty acids; pharmaceuticals, nutraceuticals, medical foods, dietary supplements, functional foods, animal foods and dosage forms comprising this composition...
|
|
WO/2024/083150A1 |
Disclosed in the present invention are a crystal form A of the NK3R antagonist represented by formula (I), and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form A comprises charac...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/085105A1 |
A purpose of the present invention is to provide an anti-inflammatory agent, a TNF-α production inhibitor, and an IL-10 production promotor which contain a plant-derived active ingredient. Another purpose of the present invention is to ...
|
|
WO/2024/083705A1 |
The present invention covers the use of furoindazole compounds of general formula (I): (I) in which R1, R2, R3, R4, R5, R6, R7a, and R7b are as defined herein, for the treatment or prophylaxis of diseases, in particular of inflammatory-d...
|
|
WO/2024/083919A1 |
The present invention relates to use of inhibitors of the potassium channel Kv1.3 in therapeutic methods, in particular wherein the methods comprise administering the inhibitor to a subject at particular intervals.
|
|
WO/2024/084189A1 |
The present invention relates to the treatment of diseases associated with inflammation including solid cancers. More particularly, certain methods relate to the administration (e.g., intravenously) of polyhedrin protein (PODS) crystals ...
|
|
WO/2024/082347A1 |
A nanomaterial capable of resisting inflammations caused by interleukin 1 and tumor necrosis factors, and a preparation method therefor and the use thereof. The nanomaterial used in the present invention has the advantages of a large spe...
|
|
WO/2024/083933A1 |
There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...
|
|
WO/2024/079647A1 |
The present invention relates to a composition comprising at least one psychedelic tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably from psychedelic psilocybin mushrooms belonging to the Psilocybe gen...
|
|
WO/2024/081893A1 |
The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and/or degradation and uses of the same in the t...
|
|
WO/2024/079206A1 |
The present invention relates to crystalline form I and form II of (2S,5R)-5-(2- chlorophenyl)- 1-(2'-methoxy- [1,1 '-biphenyl] -4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof.
|
|
WO/2024/080854A1 |
The present disclosure relates to a fusion molecule is capable of binding to an antigenic substance of which an elevated level or excessive amount causes or results in an immunological disease and inducing phagocytosis, thereby removing,...
|
|
WO/2024/079682A1 |
The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
|
|
WO/2024/079648A1 |
A controlled release delivery system comprising: a) polymeric spheres comprising at least one psychedelic compound of the class of tryptamines, phenethylamines and/or lysergamides, preferably psilocybin, psilocin, LSD, DMT, ibogaine, mes...
|
|
WO/2024/081146A1 |
Provided are monoclonal antibodies that specifically bind to human precathepsin L, antigen-binding fragments thereof, and pharmaceutical compositions comprising the antibodies and fragments, as well as methods of treatment of sepsis, rhe...
|
